Insider Trading November 19, 2026 09:05 PM

United Therapeutics EVP Mahon Offloads $4.69 Million in Stock Under 10b5-1 Plan

The general counsel exercised options and sold 8,300 shares at prices between $554.50 and $577.31, leaving him with 45,172 shares.

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
UTHR

Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp (NASDAQ:UTHR), sold 8,300 shares of common stock for approximately $4.69 million on November 19, 2026, according to a regulatory filing. The sales, at prices ranging from $554.50 to $577.31, were executed under a pre-arranged 10b5-1 trading plan adopted on August 11, 2025. Prior to the sales, Mahon exercised options on 8,300 shares at an exercise price of $146.03, for a total acquisition value of $1,212,049. After the transactions, he directly holds 45,172 shares. The insider sale comes as United Therapeutics trades near $559, with a market capitalization of $23.81 billion. The company recently reported record third-quarter revenue of $832.5 million, surpassing estimates, though earnings per share fell short. Several analysts raised their price targets following the results.

United Therapeutics EVP Mahon Offloads $4.69 Million in Stock Under 10b5-1 Plan
UTHR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Paul A. Mahon, EVP and General Counsel of United Therapeutics, sold 8,300 shares for approximately $4.69 million under a 10b5-1 trading plan adopted on August 11, 2025.
  • The sales occurred at prices between $554.50 and $577.31 per share, following the exercise of options at $146.03 per share.
  • United Therapeutics recently reported record third-quarter revenue of $832.5 million, though earnings per share fell short of estimates.
  • Several analysts raised their price targets on UTHR following the quarterly results, reflecting confidence in the company’s commercial strategies.

United Therapeutics Corp (NASDAQ:UTHR) disclosed that Paul A. Mahon, its Executive Vice President and General Counsel, sold company common stock valued at approximately $4.69 million on November 19, 2026. The transactions were carried out under a pre-arranged 10b5-1 trading plan, a structure designed to allow insiders to execute trades on a predetermined schedule.

According to the filing, Mahon disposed of 8,300 shares at prices ranging from $554.50 to $577.31 per share, generating total proceeds of $4,690,228. Before the sales, he acquired the same number of shares by exercising stock options at an exercise price of $146.03 per share, for a total acquisition value of $1,212,049. Both the option exercise and the subsequent sales were executed under a 10b5-1 plan established on August 11, 2025.

Following these transactions, Mahon directly holds 45,172 shares of United Therapeutics common stock.

The insider sale comes as United Therapeutics trades near $559, with the biotechnology company maintaining a market capitalization of $23.81 billion. According to an analysis, the stock currently appears overvalued relative to its Fair Value estimate. Despite the insider transaction, the analysis highlights that the company holds more cash than debt on its balance sheet and boasts impressive gross profit margins of 86%.

In other recent news, United Therapeutics reported record third-quarter revenue of $832.5 million, surpassing Wall Street’s estimate of $785.44 million. Despite this, the company’s earnings per share fell short, registering at $5.71 compared to the forecasted $6.21. The revenue growth was primarily driven by strong demand for Tyvaso, with its revenue alone reaching $503.8 million, up 11% from the previous quarter and 5% year-over-year, exceeding consensus estimates of $458.6 million.

Raymond James responded by raising its price target for United Therapeutics to $720, maintaining an Outperform rating. Wells Fargo also adjusted its price target to $703, citing the competitive landscape concerning Yutrepia in ILD and PAH markets. H.C. Wainwright increased its price target to $660, highlighting the company’s multi-route pulmonary hypertension platform. These developments reflect ongoing confidence in United Therapeutics’ commercial strategies and product demand.

Risks

  • The stock appears overvalued relative to its Fair Value estimate, which could lead to price correction and impact investor returns.
  • Earnings per share fell short of forecasts despite record revenue, indicating potential pressure on profitability.
  • Competitive landscape concerning Yutrepia in ILD and PAH markets, as noted by Wells Fargo, could affect future market share.

More from Insider Trading

CervoMed CEO John Alam Buys $152,621 in Company Stock Nov 19, 2026 NexPoint Director Offloads $56,750 in Stock as Shares Hover Near 52-Week Low Nov 19, 2026 NexPoint Residential CFO Paul Richards Buys $14,740 in Company Stock Nov 19, 2026 Kinetik Director ISQ Global Fund II Offloads $1.78 Million in Stock Nov 19, 2026 Tempus AI CFO Offloads $446,087 in Stock to Cover Tax Obligations Nov 19, 2026